First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
$650m buys the group rights to RemeGen’s RC148.
After Aktis's $318m flotation Eikon is a bigger proposition.
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
ELVN-001 is made to look more like Terns’ TERN-701.
Data from the Ilustro trial support the initiation of the phase 3 Lucerna study.
The group’s on/off KRAS G12C inhibitor looks good, though patient numbers are small.
